Halozyme Confidential and Proprietary Third Quarter 2022 Financial and Operating Results Nasdaq: HALO November 8, 2022 Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2022) and expectations for profitability, revenue (including expectations for future milestone ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 ___________________________ HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) _______ ...

Financial Performance Highlights - The company reported second quarter revenues of $152.4 million, a 12% year-over-year increase, resulting in GAAP earnings per share of $0.16 and non-GAAP adjusted earnings per share of $0.53 [9][48] - Royalty revenue for the second quarter was $85.3 million, representing an 86% increase compared to $45.8 million in the prior year period, driven by strong uptake of Janssen's subcutaneous DARZALEX [13][46] - The company raised its full-year 2022 revenue guidance to $655 million to $685 million, up from the previous range of $530 million to $560 million, indicating a growth of 48% to 55% over 2021 [11][49] Business Line Performance - The acquisition of Antares contributed $18.7 million in revenue for the quarter, enhancing the company's product offerings and commercial capabilities [80] - The company expects royalty revenues to increase by greater than 65% over 2021, projecting $340 million to $350 million for the year [50] Market Performance - Janssen's DARZALEX reported worldwide sales of $2 billion in the second quarter, a 46% year-over-year increase, with subcutaneous formulations gaining significant market share [15][16] - Roche's Phesgo, utilizing ENHANZE technology, achieved sales of CHF325 million, a 241% increase year-over-year, indicating strong market adoption [17] Company Strategy and Industry Competition - The acquisition of Antares aligns with the company's strategy to maximize ENHANZE revenue growth and durability while expanding its product portfolio [44][43] - The company is focused on integrating Antares and expanding its commercial infrastructure, with nearly complete expansion of its field footprint to support new product launches [70][71] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the company's diversified portfolio and its ability to navigate potential impacts from drug pricing reforms, noting that biologic drugs would not be affected for 13 years post-launch [61][62] - The company anticipates continued strong operational performance and revenue growth, supported by the integration of Antares and ongoing product launches [56][94] Other Important Information - The company plans to continue its $750 million share repurchase program, with an additional $100 million planned for 2022, depending on market conditions [54][92] - The balance sheet remains strong, with a net debt-to-EBITDA ratio of 3.3 times, expected to reduce to less than three times by year-end [53] Q&A Session Summary Question: Impact of drug pricing reform on finances - Management noted that it is too early to assess the specific impact of drug pricing reform, but the diversified portfolio positions the company well [60][62] Question: Update on Antares integration - Integration activities are on track, with a focus on creating a unique high-volume auto-injector offering [68][69] Question: Non-GAAP EPS impact from Antares - Antares contributed $18.7 million in revenue for the quarter, and the full-year guidance reflects an increase in non-GAAP EPS by $0.05 per share due to the acquisition [80][81] Question: TLANDO launch and business development prospects - The company is focused on market access for TLANDO and has received positive interest from partners regarding new auto-injector options [64][83]

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Helen Torley - President & Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Mike DiFiore - Evercore Corinne Jenkins - Goldman Sachs Jessica Fye - JPM Chase Anita Dushyanth - Berenberg Capital Markets Operator Good afternoon. My name is Emma, and I will be your conference operator today. At this time, I would ...

First Quarter 2022 Financial Results Presentation May 10, 2022 Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2022) and expectations for profitability, revenue (including expectations for future milestones and royalties), operating income, and earnings-per-sha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 ___________________________ HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ___________ ...

antares making medicines better" C Investor Presentation NASDAQ: ATRS | March 2022 Safe Harbor Statement & Non-GAAP Metrics This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forwardlooking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the Compa ...

Antares Pharma, Inc. (ATRS) Q4 2021 Earnings Conference Call March 3, 2022 8:30 AM ET Company Participants Tram Bui - VP-Corporate Communications and IR Bob Apple - President and CEO Joe Renda - SVP-Commercial Peter Richardson - EVP -Research and Development and Chief Medical Officer Fred Powell - EVP and CFO Conference Call Participants Elliot Wilbur - Raymond James David Amsellem - Piper Sandler Stacy Ku - Cowen and Company Matt Kaplan - Ladenburg Thalmann Greg Fraser - Truist Securities Operator Ladies a ...

4Q and FY 2021 Financial and Operating Results NASDAQ: ATRS | March 3, 2022 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forwardlooking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the Company's ability to achieve th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 ___________________________ HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ___________________________ ...